Forodesine
Based on 20 publication(s) in Google Scholar
Forodesine (BCX-1777) is a highly potent and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50 values ranging from 0.48 to 1.57 nM for human, mouse, rat, monkey and dog PNP. Forodesine is a potent human lymphocyte proliferation inhibitor. Forodesine could induce apoptosis in leukemic cells by increasing the dGTP levels.
For research use only. We do not sell to patients.
- Purity: 99.62%
- CAS No.: 209799-67-7
- Formula: C11H14N4O4
- Molecular Weight:266.25
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Rare Diseases Drug Library
HY-L102
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Heterocyclic Compound Library
HY-L138
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Forodesine
More- Cell. 2019 Oct 31;179(4):864-879.e19. [Abstract]
- Cell Metab. 2025 Jan 7;37(1):87-103.e10. [Abstract]
- Nat Metab. 2020 Jul;2(7):635-647. [Abstract]
- Nucleic Acids Res. 2020 Sep 25;48(17):e101. [Abstract]
- Med. 2026 Mar 27:101078. [Abstract]
- Biosens Bioelectron. 2020 Dec 1:169:112616. [Abstract]
- Int J Biol Sci. 2023 Jan 1;19(3):772-788. [Abstract]
- Chem Sci. 2024 May 14;15(23):8922-8933. [Abstract]
- Cell Rep. 2020 May 12;31(6):107640. [Abstract]
- J Med Chem. 2023 May 25;66(10):6652-6681. [Abstract]
- Plant J. 2024 Mar;117(5):1432-1452. [Abstract]
- Am J Physiol Cell Physiol. 2026 Jan 1;330(1):C142-C154. [Abstract]
- Oncol Res. 2025 Dec 30;34(1):13. [Abstract]
- Neurochem Res. 2024 Nov 16;50(1):13. [Abstract]
- J Biol Chem. 2022 May;298(5):101876. [Abstract]
- Biol Reprod. 2026 Jan 12:ioag007. [Abstract]
- bioRxiv. 2026 May 18.
- Blood Immunol Cell Ther. 2026 Jan 12.
- SSRN. 2024 Mar 14.
- bioRxiv. 2019 Oct.
Customer Validation & Images
-
Histological Imaging/Staining
-
Bio/Physico-chemical Assay
-
WB
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
Biological Activity
IC50: 1.19 nM (Human PNP), 0.48 nM (Mouse PNP), 1.24 nM (Rat PNP), 0.66 nM (Monkey PNP) and 1.57 nM (Dog PNP)[2]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | CC50 |
0.003 μM
Compound: Forodesine
|
Cytotoxicity against human CCRF-CEM cells assessed as cell viability incubated for 72 hrs by XTT assay
Cytotoxicity against human CCRF-CEM cells assessed as cell viability incubated for 72 hrs by XTT assay
|
[PMID: 37134237] |
| Jurkat | CC50 |
0.003 μM
Compound: Forodesine
|
Cytotoxicity against human Jurkat cells assessed as cell viability incubated for 72 hrs by XTT assay
Cytotoxicity against human Jurkat cells assessed as cell viability incubated for 72 hrs by XTT assay
|
[PMID: 37134237] |
| MOLT-4 | CC50 |
0.004 μM
Compound: Forodesine
|
Cytotoxicity against human MOLT-4 cells assessed as cell viability incubated for 72 hrs by XTT assay
Cytotoxicity against human MOLT-4 cells assessed as cell viability incubated for 72 hrs by XTT assay
|
[PMID: 37134237] |
| MRC5 | IC50 |
>64 μM
Compound: ImmH
|
Cytotoxicity against human MRC5 SV2 cells after 48 hrs
Cytotoxicity against human MRC5 SV2 cells after 48 hrs
|
[PMID: 20194690] |
Forodesine (10-30 μM; 24 and 48 hours; RPMI-8226, MOLT-4 and 5T33MM cells) treatment is partially inhibition of proliferation[1].
Forodesine (10-30 μM; 24 and 48 hours; RPMI-8226, MOLT-4 and 5T33MM cells) has no effect on the MM cells at 24 hours, while it could reduce the percentage of living cells in the MOLT-4 cells with 40%[1].
Forodesine (BCX-1777), in the presence of 2'-deoxyguanosine (dGuo, 3-10 μM), inhibits human lymphocyte proliferation activated by various agents such as interleukin-2 (IL-2), mixed lymphocyte reaction (MLR) and phytohemagglutinin (PHA) (IC50 values < 0.1-0.38 μM)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human RPMI-8226, human MOLT-4 (T-ALL) cells, 5T33MM (Multiple myeloma, MM)
-
Concentration:10 μM, 20 μM, 30 μM
-
Incubation Time:24 and 48 hours
-
Result:At the effects at 48 hours, a complete block in proliferation in the MOLT-4 cells and 15% reduction in the 5T33MM cells.
-
Cell Line:Human RPMI-8226, human MOLT-4 (T-ALL) cells, 5T33MM (Multiple myeloma, MM)
-
Concentration:10 μM, 20 μM, 30 μM
-
Incubation Time:24 and 48 hours
-
Result:A limited induction of apoptosis.
At a single dose of 10 mg/kg in mice, Forodesine elevates dGuo to approximately 5 μM[2].
n the human peripheral blood lymphocyte severe combined immunodeficiency (hu-PBL-SCID) mouse model, Forodesine is effective in prolonging the life span 2-fold or more[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 209799-67-7
-
Appearance Solid
-
Molecular Weight 266.25
-
Formula C11H14N4O4
-
Color White to yellow
-
SMILES
O=C1C(NC=C2[C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)=C2NC=N1
-
Synonyms
BCX-1777; Immucillin-H
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (20)
-
Journal Impact Factor
-
Most Recent
-
Cell
Stress-Induced Metabolic Disorder in Peripheral CD4+ T Cells Leads to Anxiety-like Behavior. [Abstract]2019 Oct 31;179(4):864-879.e19. PMID: 31675497 -
Cell Metab
Stress triggers irritable bowel syndrome with diarrhea through a spermidine-mediated decline in type I interferon. [Abstract]2025 Jan 7;37(1):87-103.e10. PMID: 39366386 -
Nat Metab
Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction. [Abstract]2020 Jul;2(7):635-647. PMID: 32694789 -
Nucleic Acids Res
2020 Sep 25;48(17):e101. PMID: 32797156 -
Med
Large-scale quantitative metabolomics and mass spectrometry imaging define the metabolic atlas in human acute type A aortic dissection. [Abstract]2026 Mar 27:101078. PMID: 41903544 -
Biosens Bioelectron
A thermophoresis-based biosensor for real-time detection of inorganic phosphate during enzymatic reactions. [Abstract]2020 Dec 1:169:112616. PMID: 32979591 -
Int J Biol Sci
Xanthine dehydrogenase rewires metabolism and the survival of nutrient deprived lung adenocarcinoma cells by facilitating UPR and autophagic degradation. [Abstract]2023 Jan 1;19(3):772-788. PMID: 36778128 -
Chem Sci
2024 May 14;15(23):8922-8933. PMID: 38873061
Forodesine purchased from MedChemExpress. Usage Cited in: Chem Sci. 2024 May 14;15(23):8922-8933. [Abstract]
Dose-dependent inhibition of PNP activity (20 U/L) by Forodesine (1-5 μM; 60 min) using MPR-AuNCs as luminescent probes. The inset shows structure of Forodesine.
-
Cell Rep
SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP. [Abstract]2020 May 12;31(6):107640. PMID: 32402273 -
J Med Chem
Design, Synthesis, Biological Evaluation, and Crystallographic Study of Novel Purine Nucleoside Phosphorylase Inhibitors. [Abstract]2023 May 25;66(10):6652-6681. PMID: 37134237 -
Plant J
Plant nucleoside N-ribohydrolases: riboside binding and role in nitrogen storage mobilization. [Abstract]2024 Mar;117(5):1432-1452. PMID: 38044809 -
Am J Physiol Cell Physiol
2026 Jan 1;330(1):C142-C154. PMID: 41269663 -
Oncol Res
PNP as a Metabolic and Prognostic Driver of Breast Cancer Aggressiveness: Insights from Patient Tissue and Cell Models. [Abstract]2025 Dec 30;34(1):13. PMID: 41502507
Forodesine purchased from MedChemExpress. Usage Cited in: Oncol Res. 2025 Dec 30;34(1):13. [Abstract]
Correlation between PNP and HER-2 in SKBR3 cells. Western blot analysis showing protein expression levels of HER-2 and PNP in SKBR3 cells treated with vehicle control (CTL), Forodesine (BCX-1777, a PNP inhibitor; 10 μM; 48 h), or trastuzumab (a HER-2 inhibitor). The results showed that inhibition of PNP using BCX-1777 resulted in significant (p < 0.01) upregulation of HER-2 by ~1.45 fold.
Forodesine purchased from MedChemExpress. Usage Cited in: Oncol Res. 2025 Dec 30;34(1):13. [Abstract]
SKBR3 cell viability was assessed using the MTT assay and expressed as a percentage relative to untreated control (CTL) cells. Data shown are representative blots from three independent biological replicates (n = 3). The results showed that treatment with Forodesine (BCX-1777, 10 μM; 48 h) alone, a pharmacological PNP inhibitor, significantly reduced the cell viability by ~30%. A combination of BCX-1777 with trastuzumab resulted in a further reduction in the cell viability (~34%, p < 0.01). These results demonstrated that inhibition of PNP enhanced the cytotoxic effect of HER-2 inhibition.
-
Neurochem Res
2024 Nov 16;50(1):13. PMID: 39549173 -
J Biol Chem
Entecavir competitively inhibits deoxyguanosine and deoxyadenosine phosphorylation in isolated mitochondria and the perfused rat heart. [Abstract]2022 May;298(5):101876. PMID: 35358513 -
Biol Reprod
2026 Jan 12:ioag007. PMID: 41524735
Forodesine purchased from MedChemExpress. Usage Cited in: Biol Reprod. 2026 Jan 12:ioag007. [Abstract]
The adolescent mice were administered water either with or without 0-15 mg/kg Forodesine (BCX-1777) for 1 week, and then the ovaries were obtained for immunofluorescence and hematoxylin staining. The results showed that compared with the control, oral administration of 10 and 15 mg/kg BCX-1777 significantly decreased the number of growing follicles in the ovaries.
Forodesine purchased from MedChemExpress. Usage Cited in: Biol Reprod. 2026 Jan 12:ioag007. [Abstract]
The adolescent mice were administered water either with or without 0-15 mg/kg Forodesine (BCX-1777) for 1 week, and then the ovaries were obtained for hypoxanthine concentration detection. The results showed that, compared with the control, oral administration of 10 and 15 mg/kg BCX-1777 significantly decreased hypoxanthine levels in the ovaries.
-
-
-
-
Solvent & Solubility
DMSO : 100 mg/mL (375.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 20 mg/mL (75.12 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Bieghs L, et al. The effects of forodesine in murine and human multiple myeloma cells. Adv Hematol. 2010;2010:131895. [Content Brief]
[2]. Bantia S, et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent. Int Immunopharmacol. 2001 Jun;1(6):1199-210. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.7559 mL | 18.7793 mL | 37.5587 mL | 93.8967 mL |
| 5 mM | 0.7512 mL | 3.7559 mL | 7.5117 mL | 18.7793 mL | |
| 10 mM | 0.3756 mL | 1.8779 mL | 3.7559 mL | 9.3897 mL | |
| 15 mM | 0.2504 mL | 1.2520 mL | 2.5039 mL | 6.2598 mL | |
| 20 mM | 0.1878 mL | 0.9390 mL | 1.8779 mL | 4.6948 mL | |
| 25 mM | 0.1502 mL | 0.7512 mL | 1.5023 mL | 3.7559 mL | |
| 30 mM | 0.1252 mL | 0.6260 mL | 1.2520 mL | 3.1299 mL | |
| 40 mM | 0.0939 mL | 0.4695 mL | 0.9390 mL | 2.3474 mL | |
| 50 mM | 0.0751 mL | 0.3756 mL | 0.7512 mL | 1.8779 mL | |
| 60 mM | 0.0626 mL | 0.3130 mL | 0.6260 mL | 1.5649 mL | |
| DMSO | 80 mM | 0.0469 mL | 0.2347 mL | 0.4695 mL | 1.1737 mL |
| 100 mM | 0.0376 mL | 0.1878 mL | 0.3756 mL | 0.9390 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Forodesine Related Classifications
HY-16210 Related Classifications
Powered by Bioz